Targeting HDL-cholesterol to reduce residual cardiovascular risk

Current Opinion in Lipidology

Volumn 23, Issue 2, 2012, Pages 172-174

  Iacob, Alma O ^a   Choudhury, Robin P ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DISEASE COURSE; DRUG TARGETING; EDITORIAL; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; MACROPHAGE; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; PYRIMIDINES; PYRROLES; RISK FACTORS; SULFONAMIDES;

EID: 84858756420     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835135bd     Document Type: Editorial

References (14)

1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504. (Pubitemid 38477774)
2. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078-2087.
3. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256:2835-2838. (Pubitemid 17178361)
4. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893-1900.
5. Heart Protection Study of cholesterol. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
6. Jafri H, Alsheikh-Ali AA, Karas RS. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153:800-808.
7. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009; 29:424-430.
8. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-1310. (Pubitemid 47481452)
9. Haase CL, Tybjaerg-Hansen A, Grande P, et al. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010; 95:E500-E510.
10. Haase CL, Tybjaerg-Hansen A, Ali Qayyum A, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian Randomization Study of HDL cholesterol in 54500 individuals. J Clin Endocrinol Metab 2011; Published online before print: November 16, 2011, doi:10.1210/jc.2011-1846.
11. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1241. (Pubitemid 20123768)
12. Choudhury RP, Rong JX, Trogan E, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004; 24:1904-1909. (Pubitemid 39350311)
13. Feig JE, Rong JX, Shamir R, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocytederived cells. Proc Natl Acad Sci USA 2011; 108:7166-7171.
14. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.